The U.S. Department Health and Human Services (HHS) has awarded Moderna $176 million to create an mRNA-based vaccine against pandemic influenza. This announcement has led several discussions comparing the functioning and efficiency of various COVID-19 vaccines. Moreover, Moderna's clinical trial for its mRNA vaccines has progressed to phase three, with FDA recently approving the mRNA RSV vaccine for older adults. The company also continues to make strides on the cancer front, leveraging mRNA's potential for personalized treatments. Recently, Moderna's value, however, has taken a hit, losing 27% over two days. Mixed reports of progress and setbacks have indicated an uncertain outlook for the stock. Notably, Moderna has started developing a manufacturing site in China and has received funding for its influenza program. Profit surprises have been recorded in its quarters despite sinking Covid vaccine demand, and the European Patent Office has declared Moderna mRNA patent invalid, a potential win for Moderna in the patent war.
Moderna MRNA News Analytics from Wed, 13 Sep 2023 07:00:00 GMT to Sat, 10 Aug 2024 19:30:01 GMT - Rating -3 - Innovation 8 - Information 5 - Rumor -3
